Photo: miniseries/Getty Images
Venture capital firm Santé Ventures announced the close of its largest fund to date, raising $330 million in committed capital, exceeding its $300 million target.
The firm's Fund V will invest in innovative biotechnology, medical technology and digital healthcare companies.
WHAT IT DOES
Santé Ventures, founded in 2006, focuses on early-stage startups that aim to improve patient care, particularly in areas of clinical complexity, capital inefficiency or outdated care delivery models.
"Fund V represents a continuation of our mission to partner with exceptional entrepreneurs driving breakthrough science and transformative healthcare solutions," Kevin Lalande, founding managing director and chief investment officer at Santé, said in a statement.
"We are deeply grateful for the support of our limited partners, who share our conviction that innovation at the intersection of science, medicine and technology can fundamentally improve patient outcomes."
MARKET SNAPSHOT
The investment firm touts having over $1 billion in capital under management.
Its current portfolio companies include value-based oncology platform Reimagine Care and OutcomesAI, which combines AI voice agents with licensed nurses to deliver care across pharma, health systems and virtual care settings.
Primary care-focused data and analytics company Rise Health is also part of Santé Ventures' portfolio, as is tech-enabled clinical navigation and care services platform CareHive and Graici, which offers a platform that aims to automate access to healthcare, educational and other services using an agentic AI-enabled virtual assistant.
